Cargando…
Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
Elderly patients with diabetes are at high risk of polypharmacy because of multiple coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients, who may already have age-related sensory and cognitive deficits; such deficits may dela...
Autores principales: | Onoviran, Olusola F., Li, Dongming, Toombs Smith, Sarah, Raji, Mukaila A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628533/ https://www.ncbi.nlm.nih.gov/pubmed/31321014 http://dx.doi.org/10.1177/2040622319862691 |
Ejemplares similares
-
The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
por: Sultana, Rizwana, et al.
Publicado: (2022) -
Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review
por: Kanwar, Meeta K, et al.
Publicado: (2022) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014) -
Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)